Schafer Cullen Capital Management’s Charles River Laboratories CRL Stock Holding History

Schafer Cullen Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-67,930	Closed	-$3.64M	–	326
2014 Q2	$3.64M	Sell	67,930 -3,422	-5%	-$188K	0.03%	189
2014 Q1	$4.3M	Sell	71,352 -1,206	-2%	-$70.3K	0.04%	162
2013 Q4	$3.85M	Sell	72,558 -537	-0.7%	-$27K	0.04%	174
2013 Q3	$3.38M	Sell	73,095 -39,408	-35%	-$1.81M	0.04%	184
2013 Q2	$4.62M	Buy	+112,503	New	+$4.82M	0.06%	145

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fairpointe Capital Chicago, Illinois $66.3M AUM 101.32% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Schafer Cullen Capital Management's CRL Position: Q3 2014 in Review

Schafer Cullen Capital Management sold out of Charles River Laboratories (CRL) in Q3 2014, closing a stake of 67,930 shares — an estimated $3.64M sold.

Schafer Cullen Capital Management first reported a position in CRL in Q2 2013 and held it in 5 quarters. The position peaked at $4.62M in Q2 2013. 255 funds tracked by Wall St. Rank hold CRL as of Q3 2014.

Schafer Cullen Capital Management reported no remaining Charles River Laboratories position as of Q3 2014 after selling out during the quarter.
Schafer Cullen Capital Management sold 67,930 Charles River Laboratories shares in Q3 2014, an estimated $3.64M.
Schafer Cullen Capital Management first reported a position in Charles River Laboratories in Q2 2013 and held it in 5 quarters.
Schafer Cullen Capital Management's Charles River Laboratories position peaked at $4.62M in Q2 2013.
255 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2014.

Based on Schafer Cullen Capital Management's 13F filing for Q3 2014, filed 12 Nov 2014.